RECURSION PHARMACEUTICALS, INC. (RXRX): restructuring charge — Recursion cuts workforce ~20%, extends cash runway to Q4 2027; $11M severance charges

RECURSION PHARMACEUTICALS, INC.

Workforce reduction of ~20%; expects ~$11M in severance and related costs in 2025.
Cash runway now projected into Q4 2027; cash burn guidance <$450M in 2025, <$390M in 2026.
Expects Q2 2025 cash above $500M; includes $28M R&D tax credit and >$100M potential milestone inflows by end 2026.
Reduction part of streamlined operating strategy and post-integration transitions.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

RECURSION PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $11 million (approximately 20%).

Type: restructuring
Charge: approximately $11 million
Headcount: approximately 20%

Exact text from the filing

into the fourth quarter of 2027. These changes are expected to result in a workforce reduction of approximately 20%. The Company estimates that it will incur approximately $11 million in charges in connection with the workforce reduction, consisting of severance payments, employee benefits, and related costs, substantially all of which the Company expects to

View on SEC.gov

Browse all restructurings & charges →

RECURSION PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001193125-25-138138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.